Clients

Take a look at our work and the interviews that show how we help our clients grow. The Lavery Signature is our commitment to a strategic partnership where we put your success first. 

  1. Client work

    Luqia’s launch: Lavery is proud to have acted as lead legal adviser

    Today marks a significant milestone for the innovation ecosystem in Quebec and Canada. Formed through the merger of the activities of the Institut national d’optique (INO) and the Centre de recherche informatique de Montréal (CRIM), Luqia is a major industrial innovation laboratory specialising in artificial intelligence and photonics, dedicated to Canadian businesses. Drawing on the expertise of more than 250 specialists, Luqia aims, among other things, to accelerate the development and industrialisation of critical technologies and to help strengthen the capabilities of National Defence. In this context, Lavery has supported CRIM and INO in transforming a shared ambition into a robust legal structure, commensurate with this large-scale project. Lavery would like to highlight the work of the dedicated team, led by André Vautour (CRIM’s legal adviser for several years) and Selena Lu, as well as the contributions of Radia Amina Djouaher, Siddhartha Borissov-Beausoleil, Paul Martel, Marc-André Landry, Brittany Carson, Jessica Parent, Geneviève Bergeron, Diane L’Écuyer, Ana Cristina Nascimento and Annie Groleau. Congratulations to the teams at INO and CRIM on this major achievement. Lavery wishes them every success with Luqia, which is set to become a catalyst for the industrialisation of critical technologies in AI, advanced photonics and quantum technology.

    Read more

  2. Client work

    Lavery supports Logient in its merger with Onepoint and the creation of Wepoint

    Lavery is pleased to announce that it acted as legal counsel to Logient in the transaction that saw French consulting group Onepoint acquire Logient nventive, giving rise to Wepoint, a new North American player in technology and consulting services. The new entity brings together close to 600 experts, including 450 from Logient nventive and 150 from Onepoint Canada. It plans to expand its team to 1,500 AI experts and generate $250 million in revenue by 2030. Wepoint combines complementary expertise in cloud solutions, AI, data, consulting, and technology products, with plans for the Montréal team to play a key role in its North American operations. The merger is creating a model that combines consulting excellence, local expertise, and large-scale innovation capacity, reflecting the technology and consulting sector’s trend toward consolidation and growth. The Lavery team that handled the transaction was led by Étienne Brassard and included Bernard Trang, Julie Aubin-Perron, Jen Deruchie and Arielle Supino. About Lavery Lavery is the leading independent law firm in Quebec. Its more than 200 professionals, based in Montréal, Quebec, Sherbrooke and Trois-Rivières, work every day to offer a full range of legal services to organizations doing business in Quebec. Recognized by the most prestigious legal directories, Lavery professionals are at the heart of what is happening in the business world and are actively involved in their communities. The firm's expertise is frequently sought after by numerous national and international partners to provide support in cases under Quebec jurisdiction.

    Read more

  3. Client work

    Lavery supports Moov AI with its sale to Publicis Groupe

    On March 27, 2025, Moov AI, Canada’s leading artificial intelligence and data solutions company, announced that it entered into a definitive agreement to be acquired by Publicis Groupe. The combination of Moov AI’s best-in-class consulting, proprietary solutions and insights coupled with Publicis Groupe’s CoreAI offering will add a powerful AI-driven engine and set of capabilities for Publicis Groupe Canada to leverage in-market and with its clients. Francis Dumoulin had the privilege of representing and advising Moov AI shareholders in the sale to Publicis Groupe, with Alexandre Hébert’s support and Siddhartha Borissov-Beausoleil’s contribution in closing the transaction. About Lavery Lavery is the leading independent law firm in Québec. Its more than 200 professionals, based in Montréal, Québec City, Sherbrooke and Trois-Rivières, work every day to offer a full range of legal services to organizations doing business in Québec. Recognized by the most prestigious legal directories, Lavery professionals are at the heart of what is happening in the business world and are actively involved in their communities. The firm's expertise is frequently sought after by numerous national and international partners to provide support in cases under Québec jurisdiction.

    Read more

  4. Client work

    Lavery represents ImmunoPrecise Antibodies as it acquires BioStrand

    On March 29, 2022, ImmunoPrecise Antibodies Ltd (IPA) announced that it acquired BioStrand BV, BioKey BV, and BioClue BV (together, “BioStrand”), a group of Belgian entities pioneers in the field of bioinformatics and biotechnology. With this €20 million acquisition, IPA will be able to leverage BioStrand’s revolutionary AI-powered methodology to accelerate the development of therapeutic antibody solutions. In addition to creating synergies with its subsidiaries, IPA expects to develop new markets with this revolutionary technology and strengthen its position as a world leader in biotherapeutics. Lavery was privileged to support IPA in this cross-border transaction by providing specialized expertise in cybersecurity, intellectual property, securities and mergers and acquisitions. The Lavery team was led by Selena Lu (transactional) and included Eric Lavallée (technology and intellectual property), Serge Shahinian (intellectual property), Sébastien Vézina (securities), Catherine Méthot (transactional), Jean-Paul Timothée (securities and transactional), Siddhartha Borissov-Beausoleil (transactional), Mylène Vallières (securities) and Marie-Claude Côté (securities). ImmunoPrecise Antibodies Ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases.

    Read more